How much funding has AnHeart Therapeutics raised?

AnHeart Therapeutics has raised $75.6M in total funding, most recently a Series B round.

Who are AnHeart Therapeutics's investors?

AnHeart Therapeutics's investors include Decheng Capital, Vertex Ventures China, Cenova Capital, Innovent Biologics, Laurion Capital Management.

When was AnHeart Therapeutics founded?

AnHeart Therapeutics was founded in 2018.

Where is AnHeart Therapeutics headquartered?

AnHeart Therapeutics is headquartered in New York, China.

What industry is AnHeart Therapeutics in?

AnHeart Therapeutics operates in Biotech, Oncology, Healthcare.

How many employees does AnHeart Therapeutics have?

AnHeart Therapeutics has 51-200 employees.

AnHeart Therapeutics

Acquired

New York, China · Founded 2018 · $75.6M raised

Biotech

Oncology

Healthcare

Headquarters: New York
Employees: 51–200
Founded: 2018
Business Model: B2B

Website: anhearttherapeutics.com
Total Funding: $75.6M
Last Round: $61.0M Series BDec 2021
Rounds: 3

About

AnHeart Therapeutics is a clinical-stage global biopharmaceutical company founded in 2018 and headquartered in New York City, with significant operations in China. The company focused on developing precision oncology therapeutics, most notably taletrectinib, a next-generation ROS1/NTRK inhibitor targeting ROS1 fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors. AnHeart built a broad pipeline addressing underserved cancer subtypes and was acquired by Nuvation Bio in April 2024 in an all-stock transaction, transforming Nuvation into a late-stage global oncology company with commercial-stage potential.

Summary

AnHeart Therapeutics is a Biotech company based in New York, China, founded in 2018. It has raised $75.6M in total across 3 rounds, most recently a $61.0M Series B round in Dec 2021. Investors include Decheng Capital, Vertex Ventures China and Cenova Capital.